Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivir and Guangdong Lantai Viewland Pharmaceutical have signed a licensing agreement on a non-nucleoside HIV reverse transcriptase inhibitor in late preclinical development.
Subscribe to our email newsletter
Under the terms of the agreement Guangdong Lantai Viewland Pharmaceutical will make a payment to Medivir by transferring equity. In addition Guangdong Lantai Viewland Pharmaceutical will pay royalties on sales for both oral and topical use of the inhibitor, MIV-160. Guangdong Lantai Viewland Pharmaceutical will have responsibility for the development of MIV-160 and commercialization in China. Medivir retains the rights to MIV-160 for all others territories.
Medivir said MIV-160 exhibits excellent properties against resistant HIV selected by use of present non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs).
Guangdong Lantai Viewland Pharmaceutical will potentially develop MIV-160 for three different products; an oral treatment regime, a vaginal microbicide and coating of condoms.
Use of condoms remains the best way of preventing HIV mucosal transmission; however published evidence suggests that use of male latex condoms on an annual basis only by 85% prevents transmission of HIV. This calls for the use of new condoms with an extra shield and also for protective methods to be used by women.
According to Medivir, MIV-160 inactivates HIV also outside a cell and this provides a cost-effective disinfectant/chemical barrier to prevent HIV transmission.